16 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26303893	93	A novel series of indazole-/indole-based glucagon receptor antagonists.	Merck Research Laboratories
24881566	140	Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).	Glaxosmithkline
24527772	262	The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.	Merck Research Laboratories
22708876	106	Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.	Merck Research Laboratories
19702274	31	Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.	Bristol-Myers Squibb
22119466	38	A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.	Pfizer
22030028	55	Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.	Merck Research Laboratories
22001094	78	Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.	Merck Research Laboratories
21147532	82	Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.	Merck Research Laboratories
18707090	68	Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.	Novo Nordisk
17126016	69	Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.	Merck Research Laboratories
16102966	55	Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.	Merck Research Laboratories
29153547	50	Optimization of peptide-based polyagonists for treatment of diabetes and obesity.	Novo Nordisk Research Center Indianapolis
29879354	54	Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.	Sanofi-Aventis Deutschland
21108268	67	Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.	Eberhard Karls University of Tuebingen